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Disseminated 
Bacillus Calmette-
Guérin Infection and 
Immunodeﬁ  ciency
To the Editor: Disseminated ba-
cillus Calmette-Guérin (BCG) infec-
tion has been noted in patients with 
primary immunodeﬁ  ciency. Incidence 
rates have ranged from 0.06 to 1.56 
cases per million vaccinated, and mor-
tality rates have remained at ≈60% 
(1–7).  Of 946 patients with primary 
immunodeﬁ  ciency, including 29 with 
severe combined immunodeﬁ  ciencies, 
diagnosed from 1980 through 2006 at 
the Children’s Memorial Health Insti-
tute in Warsaw, adverse events after 
BCG vaccination were observed in 16 
(8,9). All 16 were children who had 
been vaccinated at birth with BCG, 
Brazilian strain (Biomed, Lublin,       
Poland). 
Four patients with severe com-
bined immunodeﬁ  ciency showed ad-
verse reactions to BCG. Patient M.K. 
had mild inﬂ  ammation at the site of 
the BCG injection and was success-
fully treated with rifampin. The patient 
subsequently received a bone marrow 
transplant, and 2 months later poor ap-
petite, failure to thrive, and subfebrile 
condition were noted. Disseminated 
skin changes (with pus formation in 
the subcutaneous layer), osteomyeli-
tis, and multiple lesions in the liver 
were found. A skin biopsy showed 
tuberculoma formations, which were 
PCR-positive for Mycobacterium tu-
berculosis complex (Ampliﬁ  ed Myco-
Figure. Pulsed-ﬁ  eld gel electrophoresis (PFGE) banding patterns of chromosomal DNA 
of 26 isolates of vancomycin-resistant enterococci. There is a clear predominant type, 
classiﬁ  ed as type A (>80% similarity), composed of 18 isolates of Enterococcus faecium. 
There are at least 3 subtypes that display a 100% similarity.LETTERS
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bacterium Tuberculosis Direct [MTD] 
Test, Gen-Probe, Inc., San Diego, CA, 
USA) but had negative culture results. 
Complete recovery, including full im-
munologic reconstitution, was reached 
after 12 months of treatment with 
triple antituberculosis (TB) therapy 
(rifampin, isoniazid, and ciproﬂ  oxa-
cin). Patient M.C., a 6-month-old boy, 
was admitted to an intensive care unit 
because of respiratory insufﬁ  ciency. 
An unhealed BCG vaccination site 
was noted. Bronchopulmonary lavage 
samples were tested for M. bovis; posi-
tive PCR and culture results led to the 
diagnosis of disseminated BCG infec-
tion. Despite intensive anti-TB therapy, 
the child died of multiple organ failure. 
Autopsy showed typical granuloma 
formations and a hypoplastic thymus, 
typical for severe combined immuno-
deﬁ  ciency. Male patients S.D. and C.G. 
were admitted to intensive care units 
at 6 and 8 months of age, respectively, 
with lymphadenopathy and multiple 
organ insufﬁ  ciency. Each boy died of 
multiple organ failure; postmortem ex-
amination found granuloma formation 
and a hypoplastic thymus in each (8).
Eight patients with severe com-
bined immunodeﬁ   ciency had local 
adverse events after vaccination with 
BCG. Inﬂ  ammation at the vaccination 
site was observed for all 8. For all ex-
cept 1, dual anti-TB therapy (rifampin, 
isoniazid) or monotherapy was suc-
cessful. For 1 of these patients, anti-TB 
treatment was stopped 3 months after 
bone marrow transplant, but increas-
ing inﬂ   ammation and lymphadenitis 
appeared 1 month later, with positive 
PCR and negative culture results for 
Mycobacterium spp. After 12 months 
of triple anti-TB therapy, this patient 
fully      recovered.
In 2-month-old female patient, 
W.M., who had interferon-γ–receptor 
deﬁ  ciency, axillary lymphadenopathy 
with normal healing of the vaccina-
tion site was noted 7 weeks after BCG 
vaccination. Tuberculous lymphadeni-
tis was diagnosed by histopathologic 
methods. Despite dual anti-TB therapy 
and streptomycin administration, the 
girl died. At autopsy, multiple tuber-
culous granulomas were found (5).
In 4-month-old female patient 
M.K., who had interleukin-12–recep-
tor deﬁ   ciency, axillary lymphade-
nopathy with positive results from 
Mycobacterium typing was noted. 
Dual anti-TB therapy for 12 months 
produced good results.
In 7-month-old female patient 
B.B., who also had interleukin-12–
receptor deﬁ   ciency, axillary lymph-
adenopathy was noted. Mycobacteria 
PCR-positive for the M. tuberculosis 
complex were found in the purulent se-
cretion. Despite dual anti-TB therapy, 
the patient experienced 2 episodes of 
relapse. After another 2 years of anti-
TB therapy, disseminated BCG infec-
tion, with pulmonary consequences, 
developed.
In patient R.C.,  a 6-month-old 
boy, osteomyelitis was diagnosed, and 
delayed healing of the BCG vaccina-
tion scar was noted. Investigation of 
his immunologic status showed no ab-
normalities. However, because granu-
lomatous inﬂ  ammation was present in 
a bone biopsy sample and staining for 
BCG produced a positive result, triple 
anti-TB therapy was provided for 12 
months, with good results.
The literature describes >200 
cases of disseminated BCG infection 
in patients with primary immunodeﬁ  -
ciency (1–7). The diagnostic difﬁ  cul-
ties described for 8 of our patients with 
primary immunodeﬁ  ciency have been 
noted by others (1–6,8–10). In only 2 
cases was the Mycobacterium species 
successfully isolated and identiﬁ  ed as 
the M. bovis BCG strain. We propose 
novel criteria for the diagnosis of dis-
seminated BCG infection in persons 
with primary immunodeficiency 
(Table). These criteria have recently 
been submitted to the European Soci-
ety for Immunodeﬁ  ciencies.
Table. Suggested diagnostic criteria for disseminated bacillus Calmette-Guérin (BCG) infection in persons with primary 
immunodeficiency*
Diagnosis Clinical Laboratory 
Definitive Systemic symptoms such as fever or 
subfebrile status, weight loss, or stunted 
growth, and >2 areas of involvement beyond 
the site of BCG vaccination† 
Identification of Mycobacterium bovis BCG substrain from
the patient’s organs by culture and/or standard PCR, as well as  
typical histopathologic changes with granulomatous inflammation 
Probable Systemic symptoms such as fever or 
subfebrile status, weight loss or 
stunted growth, and >2 areas of 
involvement beyond the site of BCG 
vaccination†
Identification of M. tuberculosis complex from the organs by 
PCR, without differentiation of M. bovis BCG substrain or other 
members of the M. tuberculosis complex and negative 
mycobacterial cultures, with the presence of typical 
histopathologic changes with granulomatous inflammation 
Possible Systemic symptoms such as fever or 
subfebrile condition, weight loss or stunted 
growth, and >2 areas of involvement beyond 
the site of BCG vaccination† 
No identification of mycobacteria by PCR and culture, with  
presence of typical histopathologic changes with  
granulomatous inflammation 
Exclusion
criteria 
Any inflammation without typical histopathologic changes, with no isolation of M. tuberculosis complex by PCR 
analysis in patient with primary immunodeficiency 
Differential 
diagnosis
Severe, long-term inflammation with granuloma formation in patient with primary immunodeficiency 
*Male or female patient with or without genetic confirmation of severe combined immunodeficiency, interferon-γ–receptor deficiency, interleukin-12–
receptor deficiency, or other primary immunodeficiency.  
†Areas of involvement may include lymph nodes, skin, soft tissues, lungs, spleen, liver, bones. LETTERS
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We believe that patients with se-
vere combined immunodeﬁ  ciency 
and any form of mild local changes 
at the BCG injection site should be 
given single or double anti-TB ther-
apy, which should be continued until 
complete immunologic reconstitution 
occurs after bone marrow transplant. 
Severe local BCG infection with re-
gional lymph node involvement needs 
at least triple anti-TB therapy followed 
by long-term prophylaxis. Dissemi-
nated BCG infection needs anti-TB 
therapy, including >4 anti-TB drugs, 
until the patient fully recovers.
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Clindamycin-
resistant 
Streptococcus 
pneumoniae 
To the Editor: Antimicrobial 
medications classiﬁ   ed as macrolides 
(e.g., erythromycin) and lincosamides 
(e.g., clindamycin) show strong ac-
tivity against streptococci and are 
commonly used to treat community-
acquired infections caused by Strepto-
coccus pneumoniae. Moreover, these 
drugs are the recommended alterna-
tives for patients who cannot tolerate 
β-lactams.
Two main macrolide-resistant S. 
pneumoniae phenotypes have been re-
ported (1). The ﬁ  rst has a high level 
of resistance to all macrolides, lincos-
amides, ketolides, and streptogramins 
B due to ribosomal dimethylation, 23S 
rRNA mutations, or ribosomal protein 
mutations (MLSB, MSB, ML, MKSB, 
and K phenotypes). The second is 
characterized by a low-level resistance 
(e.g., MIC 2–4 mg/L) to only 14- and 
15-member ring macrolides (M phe-
notype) because of mef gene–medi-
ated active drug efﬂ  ux mechanism.
In January 2005, an erythromy-
cin-susceptible but clindamycin-resis-
tant pneumococcal strain was obtained 
from a conjunctival swab of a 10-
month-old female outpatient attending 
the daycare center of the Clinic and 
Laboratory of Infectious Diseases, 
Siena University, Siena, Italy. To our 
knowledge, such a phenotype has not 
been reported in the international lit-
erature for S. pneumoniae, although a 
similar phenotype of S. agalactiae was 
described by Malbruny et al. (2).
The  S. pneumoniae isolate was 
identiﬁ  ed by standard procedures (3) 
and conﬁ  rmed by PCR for the com-
mon capsule gene cpsA (4). Serotyp-
ing, performed by Quellung reaction, 
showed a 35F serotype. Susceptibility 
testing was carried out by disk dif-
fusion and conﬁ  rmed with E-test ac-
cording to Clinical and Laboratory 